<?xml version="1.0" encoding="ISO-8859-1"?>
<?xml-stylesheet type="text/xsl" href="helma.xsl"?>
<xmlroot xmlns:hop="http://www.helma.org/docs/guide/features/database">
  <hopobject id="2432" name="Page" prototype="Page" created="1363280116832" lastModified="1542914556716">
  <hop:parent idref="0" prototyperef="Root"/>
    <http_browser>Mozilla/4.0 (compatible; MSIE 6.0; Windows NT 5.1; SV1)</http_browser>
    <lang>en-us</lang>
    <uri>bone-update</uri>
    <http_host>127.0.0.1:8080</http_host>
    <time type="date">22.11.2018 19:22:36 UTC</time>
    <pseudoparent idref="0" prototyperef="Root"/>
    <http_remotehost>127.0.0.1</http_remotehost>
    <hopsession>127.0.0.v6p6qbuamjvt</hopsession>
    <user>default</user>
    <pvcount type="float">85.0</pvcount>
    <body>In a meeting &lt;a href=&quot;http://www.proguaru.com.br/how-much-ibuprofen-should-i-take-for-a-migraine-7684.pdf&quot;&gt;can baby take paracetamol and ibuprofen together&lt;/a&gt;  In this same article the author hosted a panel discussion with the three companies mentioned above and discussed the merits of each company&amp;#8217;s potential drug candidates. For those who believe that investing in CSCs makes for a compelling investment thesis, the best approach to take may be to buy equal dollar amounts of each of the above three companies since all three market caps are roughly the same. In this way some of the company specific risks are eliminated. While the returns of these companies are likely to be somewhat correlated, if just one company achieves their goals the gains may very well offset any potential losses incurred in the other two companies.
 </body>
    <http_language>en-US,en;q=0.8</http_language>
    <is_xhtml type="boolean">true</is_xhtml>
    <http_referer>http://beagleboard.org/bone-update/edit</http_referer>
  </hopobject>
</xmlroot>
